ATLANTIC BONE SCREEN

Atlantic Bone Screen is a leading CRO (« Contract Research Organization ») specialized in high-quality preclinical evaluation services in the field of bone and joint diseases and more particularly in bone diseases from tumor origin. Founded in 2005 by Ronan LE BOT, the CEO of the company, Atlantic Bone Screen is based in Nantes, North-West of France. The company provides a unique preclinical platform with a wide range of assays including in vitro assays with primary cells and cell lines from human and/or animal origin and in vivo assays with reliable animal models reproducing human bone pathologies. Moreover, the company offers histology/histopathology services as well as imaging services such as microCT and X-Ray analyses. Atlantic Bone Screen's expertise extends to the evaluation of biomaterials for orthopedic or dental applications. The company's services support the characterization of drug candidates, nutraceuticals, and biomaterials. In addition to its core services, Atlantic Bone Screen is also associated with sister companies like ATLANCHIM PHARMA, a custom chemical synthesis CRO and ATLANTHERA, a drug discovery company in bone research. Atlantic Bone Screen presents itself as a valuable partner for preclinical research in oncology, inflammation, musculoskeletal disorders, and osteoarticular diseases. With its high-quality offerings and expertise in the biotechnology industry, the company holds significant potential for growth and impact within the field. While specific investment information is not currently available, the company's innovative approach and niche focus make it an intriguing prospect for potential investors and venture capitalists looking for opportunities in the biotechnology sector in the future.